Zydus Lifesciences Expands Vaccine & Medtech Portfolio for FY26 Growth
Zydus Lifesciences Ltd. is ramping up its vaccines and medtech portfolio, positioning itself for double-digit revenue growth in FY26. The pharmaceutical major, which posted its highest-ever operating profit and margins in FY25, sees biologics, vaccines, and medical devices as key drivers of expansion. Vaccine Strategy & Global Expansion Medtech Expansion & Strategic Acquisitions Financial Performance…
